Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Glaucoma, Open-AngleOcular Hypertension
Interventions
DRUG

bimatoprost ophthalmic solution 0.01%

One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.

DRUG

travoprost ophthalmic solution 0.004%

One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.

DRUG

latanoprost ophthalmic solution 0.005%

One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.

Trial Locations (2)

Unknown

Rogers

Calgary

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY